Engineered donor cells take on tough leukemia in early trial
NCT ID NCT04150497
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This study tests a new treatment called UCART22 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or not responded to standard therapies. UCART22 uses immune cells from a healthy donor that are specially designed to find and attack cancer cells. The main goals are to check the treatment's safety and find the best dose, while also seeing how well it controls the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Rennes - Hopital Pontchaillou
RECRUITINGRennes, 35033, France
-
CHU de Nantes - Hôtel-Dieu
RECRUITINGNantes, 44093, France
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Hôpital Lyon Sud
RECRUITINGPierre-Bénite, 69310, France
-
Hôpital Robert Debré - Service d'hémato-immunologie
RECRUITINGParis, 75019, France
-
Hôpital Saint Louis, Unité d'Hématologie Adolescents et Jeunes Adultes Département d'Hématologie
RECRUITINGParis, 75010, France
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10021, United States
-
Roswell Park Comprehensive Cancer Center
RECRUITINGBuffalo, New York, 14263, United States
-
Sarah Cannon - Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
-
Sarah Cannon - HCA Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
Sarah Cannon - St. David's South Austin Medical Center
RECRUITINGAustin, Texas, 78704, United States
-
Sarah Cannon - Texas Transplant Institute at Methodist Hospital
RECRUITINGSan Antonio, Texas, 78229, United States
-
University of California, Los Angeles (UCLA) - Medical Center
RECRUITINGLos Angeles, California, 90095, United States
-
University of Chicago
RECRUITINGChicago, Illinois, 60647, United States
-
University of Colorado - Aurora Cancer Center
RECRUITINGAurora, Colorado, 80045, United States
-
University of Wisconsin Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53792, United States
-
Weill Medical College of Cornell University
WITHDRAWNNew York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.